Metformin

Generic Name
Metformin
Brand Names
Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
Drug Type
Small Molecule
Chemical Formula
C4H11N5
CAS Number
657-24-9
Unique Ingredient Identifier
9100L32L2N
Background

Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.

Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.

Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.

Indication

Metformin immediate-release formulations

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.

Metformin extended-release tablet (XR)

The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.

Metformin combination products

Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.

Associated Conditions
Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
Associated Therapies
-
Clinical Trials
Related News

Molecular Effects of Aspirin & Metformin on Colonic Epithelium

First Posted Date
2021-12-15
Last Posted Date
2022-05-18
Lead Sponsor
University of Edinburgh
Target Recruit Count
250
Registration Number
NCT05158374

Metformin in Children With Fragile X Syndrome

Phase 4
Recruiting
Conditions
Fragile X Syndrome
Metformin
Interventions
Drug: Placebo
Drug: Metformin
First Posted Date
2021-11-15
Last Posted Date
2024-03-07
Lead Sponsor
Children's Hospital of Fudan University
Target Recruit Count
20
Registration Number
NCT05120505
Locations
🇨🇳

Children's Hospital of Fudan University, Shanghai, Shanghai, China

Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas

First Posted Date
2021-11-01
Last Posted Date
2022-06-01
Lead Sponsor
Boehringer Ingelheim
Registration Number
NCT05102071
Locations
🇺🇸

Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, United States

Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity

First Posted Date
2021-10-28
Last Posted Date
2024-03-01
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
100
Registration Number
NCT05098470
Locations
🇺🇸

University of Virginia, Charlottesville, Virginia, United States

🇺🇸

Rita Basu, Birmingham, Alabama, United States

Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction

First Posted Date
2021-10-26
Last Posted Date
2024-09-30
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
80
Registration Number
NCT05093959
Locations
🇺🇸

Wake Forest School of Medicine, Winston-Salem, North Carolina, United States

🇺🇸

Atrium Health Sanger Heart and Vascular Clinic Institute, Charlotte, North Carolina, United States

A Study of Lazertinib (JNJ-73841937) in Healthy Participants

First Posted Date
2021-10-13
Last Posted Date
2022-06-27
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
20
Registration Number
NCT05076877
Locations
🇺🇸

PRA Health Sciences, Salt Lake City, Utah, United States

Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates

First Posted Date
2021-10-01
Last Posted Date
2022-01-11
Lead Sponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Target Recruit Count
40
Registration Number
NCT05064488
Locations
🇩🇪

Nuvisan GmbH, Neu-Ulm, Germany

Implication of Metformin Plus Aromatase Inhibitor in Obese Postmenopausal Breast Cancer Women

Phase 2
Completed
Conditions
Metformin
Breast Cancer
Interventions
Drug: Metformin
First Posted Date
2021-09-23
Last Posted Date
2021-09-23
Lead Sponsor
Tanta University
Target Recruit Count
45
Registration Number
NCT05053841

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

First Posted Date
2021-09-13
Last Posted Date
2024-10-28
Lead Sponsor
University of Oxford
Target Recruit Count
3800
Registration Number
NCT05041907
Locations
🇳🇵

Sukraraj Tropical & Infectious Disease Hospital, Kathmandu, Nepal

🇧🇷

Universidade Federal de Minas Gerais, Minas Gerais, Brazil

🇱🇦

Laos-Oxford-Mahosot Wellcome Trust Research Unit, Vientiane, Lao People's Democratic Republic

and more 4 locations

Anti-diabetic Drugs and Fatty Liver Management

First Posted Date
2021-09-13
Last Posted Date
2022-01-18
Lead Sponsor
Alexandria University
Target Recruit Count
120
Registration Number
NCT05041673
Locations
🇪🇬

Alexandria University., Alexandria, Egypt

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy